Journal ArticleOPEN ACCESS

Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases

Inflammatory Bowel Diseases (2023) 29(1) 167-171
DOI: 10.1093/ibd/izac244
10Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

For the first time, fecal mucins of Crohn's disease patients were analyzed by mass spectrometry. Compared with control subjects, Crohn's disease patients showed a significant decrease in sialylated glycans that we propose as new noninvasive tool for screening of intestinal diseases.

Author supplied keywords

Cite

CITATION STYLE

APA

Robbe Masselot, C., Cordier, C., Marsac, B., Nachury, M., Leonard, R., & Sendid, B. (2023). Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 29(1), 167–171. https://doi.org/10.1093/ibd/izac244

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free